Provider
QP5-21 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Sucraid® (sacrosidase) PAQL
Program effective Date: Jan 27, 2021
Documents & Forms Results
Displaying 2171 - 2180 of 3111 results
Provider
QP7-21 Replacement Claim Submission Guidelines
Program effective Date: Jan 27, 2021
Provider
QP6-21 MHCP Pharmacy Benefit Exclusion for OxlumoTM and Danyelza®
Program effective Date: Jan 27, 2021
Provider
QP8-21 Change in Suspect COVID-19 Diagnosis Code
Program effective Date: Jan 27, 2021
Provider
QP4-21 Commercial Pharmacy Benefit Exclusion for OxlumoTM
Program effective Date: Jan 27, 2021
Provider
QP2-21 Update for New to Market Medical Drugs: Aducanumab, Casimersen, Evinacumab, Idecabtagene Vicleucel, and Pegunigalsidase Alfa
Program effective Date: Jan 13, 2021
Provider
QP1-21 Pharmacy Benefit Update – Revised Drug-Related Prior Authorization (PA) Requirement Notification – Effective March 1, 2021
Program effective Date: Jan 13, 2021
Provider
QP3-21 Commercial and MHCP Pharmacy Benefit Exclusion for Barhemsys® and Monoferric®
Program effective Date: Jan 13, 2021
Provider
P81R1-20 Update: eviCore Healthcare Specialty Utilization Management (UM) Program - Cardiology and Radiology Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers
Program effective Date: Jan 04, 2021
Provider
P5-21 New Reimbursement Policy: Outpatient Services Prior to an Inpatient Admission
Program effective Date: Jan 04, 2021